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Multiple myeloma (MM) is a hematological neoplasm that arises
from a single clone of malignant plasma cells in the bone marrow.
In Europe, 4.6/100 000 males and 3.2/100 000 females every year
develop MM, with a median age at diagnosis around 60 years.1
The observation of a higher risk to develop MM among ﬁrst-
degree relatives of MM patients in several population-based case--
control studies supports the idea that genetic factors are involved
in MM pathogenesis.2 Therefore, several studies focusing on
various genes and pathways have tried to identify single-
nucleotide polymorphisms (SNPs) associated with the suscept-
ibility to the disease.3,4
The detoxiﬁcation and elimination of xenobiotic compounds is
one of the most investigated processes in cancer susceptibility,
with several evidences of its association with cancer risk.5 ATP-
binding cassette (ABC) subfamily B, member 1 (ABCB1 or MDR1);
subfamily G, member 2 (ABCG2 or BCRP); subfamily C, member 2
(ABCC2 or MRP2); subfamily C, member 1 (ABCC1 or MRP1) and
subfamily C, member 3 (ABCC3 or MRP3) are efﬂux pumps that
have a key role in determining the intracellular levels of xenobiotic
and toxic compounds, thus protecting cells. ABC transporters are
expressed in many tissues, including the blood, and they have
been recently showed to be characteristically expressed in
hematopoietic stem cells (HSCs).6 Beside, the exposure to
pesticides and toxic compounds, most of which are substrates
of ABC transporters, has been shown to increase MM and MGUS
Q4 risk.7,8 Therefore, it is a reasonable hypothesis that genetic
variation within these genes can affect the exposure
of hematopoietic cells to toxic compounds resulting in an
increased/decreased risk of MM.
Despite the large number of studies investigating the role of
variants in ABC transporters in cancer susceptibility, including
hematological malignancies,9,10 to date only one investigated the
role of three variants in ABCB1 gene and MM susceptibility.11
Therefore, we performed a two-phase candidate gene association
study to comprehensively evaluate the role of genetic variants of
ABCs transporter genes in relation to MM risk. We selected 54
SNPs in ABCB1, ABCG2 and ABCC2 genes using a tagging approach
to take into account for all the common genetic variability within
these genes and four additional functional polymorphisms in
ABCC1 and ABCC3 to test their impact on MM susceptibility
(a complete list of the selected SNPs is available in Supplementary
Table I). In the context of an International Consortium named
IMMEnSE (International Multiple Myeloma rESEarch), we collected
more of 700 MM cases and 900 controls from Italy, Spain, Poland,
Portugal and France. A subset of 633 MM patients and 835 healthy
controls with a similar distribution between gender and age
(w2 P¼ 0.753, Kruskal --Wallis P¼ 0.307) was available for this study
and was used for the initial screening of the 58 genetic variants
selected. Baseline characteristics of the population are reported in
Table 1. The IMMEnSE biobank is set up at the German Cancer
Research Center (DKFZ) in Heidelberg, where genotyping has
been conducted using both TaqMan (ABI, Applied Biosystems,
Foster City, CA, USA) and KASPar (KBioscence, Hoddesdon, UK)
technologies and adequate quality control procedures (as
described in the Supplementary methods). All the SNPs were in
Hardy--Weinberg Equilibrium (HWE) among controls (P40.001)
with the exception of the ABCC2 SNP rs3740073 (Po0.001) that
was therefore excluded from further analysis.
Logistic regression was used to assess the main effects of the
genetic polymorphisms on MM risk using a co-dominant and a
dominant inheritance model adjusted for age, gender and region
of origin. For each SNP, the more common allele in the controls
was assigned as the reference category (for detailed material and
methods see Supplementary Information). Of the 58 variants
screened, 13 SNPs resulted associated with MM risk in the
IMMEnSE population at the conventional P-value level of Po0.05
(Supplementary Table II). Haplotype analysis (Supplementary
Table III) and gene--gene interaction analysis did not add any
signiﬁcant information to the single SNP analysis. With the aim to
further investigate the associations found in the ﬁrst phase, an
independent case--control set of German origin was collected
through the collaboration with the Heidelberg Myeloma Group.
Using the same methodology described above, we genotyped
the 13 SNPs associated in the ﬁrst phase in 564 MM cases and
1471 healthy controls from Germany (Table 1) with a similar
distribution between genders (w2 P¼ 0.141), although age was
signiﬁcantly higher for the controls (Kruskal --Wallis P¼ 0.0001). All
the SNPs resulted in HWE among controls (P40.001). The two
ABCB1 SNPs rs2235013 and rs10256836 were replicated in the
Heidelberg population (Supplementary Table IV).
We analyzed the results for the whole population of 1197 MM
cases and 2306 controls (Supplementary Tables V, VI). Interest-
ingly, the ABCB1 SNPs rs10264990 and rs17327442 resulted
associated with MM risk reaching the P-value threshold adjusted
for multiple testing (Po0.0014; Table 2). To evaluate hetero-
geneity of the ﬁndings between populations, we performed a
meta-analysis across all the different regions in the IMMEnSE and
Heidelberg populations. Results showed the absence of statisti-
cally signiﬁcant heterogeneity among different case--control sets
and conﬁrmed the associations (Supplementary Figure 1). To
further asses the robustness of our ﬁndings, we performed
100 000 permutations to compare P-values from randomly
generated empirical distributions for the SNPs rs10264990 and
rs17327442 with the observed ones. We conﬁrmed in this way the
statistically signiﬁcant associations of the T carriers for the
rs10264990 with a decreased risk of MM (P¼ 0.015) and of the
T/T homozygous for the rs17327442 with an increased risk of MM
(P¼ 0.009; Table 2).
At the best of our knowledge, this is the largest study on
genetic susceptibility of MM and has a sufﬁcient statistical power
(over 0.80 for a co-dominant model) to detect an odds ratio¼ 1.57
at a¼ 0.0014 (study-wise signiﬁcance P-threshold) for a SNP with a
MAF¼ 0.05 in the overall population. Beside, this is the ﬁrst
comprehensive study that captures all the common genetic
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variation within ABCB1, ABCG2 and ABCC2 genes and investigates
variants in ABCC1 and ABCC3 in relation to MM risk. Our results
conﬁrm the ﬁndings of the only study already published in the
literature showing no associations of the same three ABCB1
variants previously tested (or their tag SNP) with MM risk.11
Our results suggest a possible low-penetrance role for the two
genetic variants rs10264990 and rs17327442 within ABCB1 gene in
modulating individual susceptibility to MM can be hypothesized.
The SNP rs17327442 has been already found associated with
genetic susceptibility to Crohn’s disease,12 whereas the SNP
rs10264990 has not been associated with any disease risk. Both
these SNPs are located in intronic regions of the ABCB1 gene and
no functional data have been reported to date. To explain our
observation, we investigated the putative function of the two
SNPs with the FastSNP tool.13 Although the ABCB1 SNP
rs10264990 has no known or predicted function, the genetic
ABCB1 variant rs17327442 is predicted to be an ‘intronic
enhancer’. In particular, the rs17327442_T allele is predicted to
introduce a binding site for the transcription factors T-cell acute
lymphocytic leukemia 1 (TAL1). This latter ﬁnding is particularly
intriguing. It has been shown that TAL1 is a crucial factor for HSC
differentiation and its deregulation can lead to oncogenesis in
T cells by altering several downstream genes. Several ABC family
members are regulated by TAL1, and in particular ABCG2, ABCE1
and ABCB10 are activated in erythroid cell lines after TAL1
knocking down, while ABCC1 expression is repressed.14,15
Although ABCB1 seems not to be one of the targets for TAL1
regulation, one can hypothesize that the introduction of a binding
site for the transcription factor by the rs17327442_T allele could
determine its interaction with TAL1. This could therefore result in
an aberrant regulation of ABCB1 expression during normal HSC
development. Owing to the broad spectrum of substances
transported by this pump, including regulators and mediators of
B-cell growth and survival, an alteration of its normal expression
could enhance the exposure of HSCs to mutagens or proliferating
signals that could therefore justify the increased risk to develop
MM associated with the rs17327442 T/T genotype.
In conclusion, our results suggest that genetic variants within
ABCB1 gene can have a role on the risk to develop MM.
Nevertheless the association of the ABCB1 SNP rs17327442 T/T
homozygotes with a twofold higher risk to develop MM has to be
replicated on independent populations to clarify its real impact.
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First Study Population (IMMEnSE consortium)
Pisa, Italya 115/108 (223) 62.60 (±9.90) 63 (35-87) 129/105 (234) 58.77 (±10.89) 58.5 (35-89)
Lodz, Polandb 50/47 (97) 61.80 (±10.55) 62 (39-86) 66/80 (146) 69.53 (±6.71) 69 (55-98)
Salamanca, Spainc 66/58 (124) 62.70 (±11.60) 62 (31-93) 137/125 (262) 65.56 (±12.85) 66 (24-92)
Granada, Spaind 23/36 (59) 63.25 (±10.30) 63 (39-86)
Lyon, Francee 43/32 (74) 55.60(±8.97) 57 (34-75) 47/47 (94) 33.31 (±14.80) 30 (18-60)
Braga, Portugalf 26/29 (55) 66.78 (±10.49) 68 (43-86) 54/45 (99) 60.76 (±7.72) 58 (51-85)
Total 323/310 (633) 62.10 (±10.64) 62 (31-93) 433/402 (835) 60.15 (±15.18) 62 (18-98)
Replication Study population (Heidelberg Myeloma Group)
Heidelberg, Germanyg 323/241 (564) 54.58 (±7.82) 56 (25-66) 789/682 (1471) 56.31 (±9.89) 59 (18-68)
Overall population
Total 646/551 (1197) 58.43 (±10.10) 59 (25-93) 1222/1084 (2306) 56.78 (±12.73) 59 (18-98)
aDeparment of Oncology, Transplants and Advanced Technologies, Section of Haematology, Pisa University Hospital, Pisa, Italy bDeparment of
Hematology, Medical University of Lodz, Lodz, Poland cHematology division, University Hospital of Salamanca, Salamanca, Spain dHematology and
Hemotherapy Department, University Hospital Virgen de las Nieves, Granada, Spain eHospices Civils de Lyon, Lyon, France fLife and Health Sciences Research
Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal gMedizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany.
Table 2. Significant associations of ABCB1 SNPs rs10264990 and rs17327442 with MM risk in the overall population
SNP (rs) Cases N (%) Controls N (%) ORa 95%CI P-value P-trend P-perm
ABCB1 rs10264990
C/C 549 (47.1) 958 (41.7) 1 Ref. -- 0.023
C/T 475 (40.7) 1059 (46.0) 0.77 0.66 - 0.90 0.001
T/T 142 (12.2) 283 (12.3) 0.85 0.68 - 1.07 0.171 0.869*
C/T + T/T 617 (52.9) 1342 (58.3) 0.79 0.68 - 0.91 0.001 0.015**
ABCB1 rs17327442
A/A 824 (69.7) 1600 (69.9) 1 Ref. -- 0.191
A/T 309 (26.1) 643 (28.1) 0.92 0.78 - 1.08 0.309
T/T 50 (4.2) 46 (2.0) 1.99 1.32 - 3.02 0.001 0.009*
A/T + T/T 359 (30.3) 689 (30.1) 0.99 0.85 - 1.16 0.928 1**
Genotype distribution among MM cases and controls in the overall population of the ABCB1 SNPs rs10264990 and rs17327442. aOdds Ratios (OR) are adjusted
for age, gender and region of origin. Differences in sample numbers are due to failures in genotyping. Results in bold show Po0.05. *P-value obtained after
100 000 permutations following a co-dominant model. **P-value obtained after 100 000 permutations following a dominant model.
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